darunavir has been researched along with efavirenz in 31 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 3,110 | 631 | 1,611 |
| Protein | Taxonomy | darunavir (IC50) | efavirenz (IC50) |
|---|---|---|---|
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Prothrombin | Bos taurus (cattle) | 0.022 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 25 (80.65) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Hamburger, M; Hamy, F; Klimkait, T; Louvel, S; Mojarrab, M; Potterat, O; Sanglier, JJ; Vidal, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cen, S; Dong, B; Guo, Y; Liang, C; Ma, L; Wang, J; Wang, Y; Wang, Z; Wen, J; Zhang, G; Zhou, J; Zhu, M | 1 |
| Cen, S; Dong, B; Ma, L; Shan, Q; Wang, J; Wang, M; Wang, Y; Wen, J; Zhang, G; Zhou, J; Zhu, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, VJ | 1 |
| Banno, K; Hirano, A; Kaneda, T; Kudaka, Y; Okumura, N; Takahashi, M | 1 |
| de Souza, DF; Diaz, RS; Inocencio, LA; Janini, LM; Munerato, P; Oliveros, MP; Pereira, AA; Sucupira, MC | 1 |
| Flexner, C; Lee, L; Pham, P; Shen, P; Soon, GH; Yong, EL | 1 |
| Flexner, C; Lee, LS; Pham, P; Shen, P; Soon, GH; Yong, EL | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Flexner, C; Lee, LS; Pham, P | 1 |
| Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Fletcher, CV; Podany, AT; Robbins, BL; Winchester, LC | 1 |
| Alegre, F; Apostolova, N; Blas-García, A; Esplugues, JV; Funes, HA; Martínez, E; Polo, M | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Aberg, JA; Ma, Q; Malvestutto, CD; Morse, GD; Underberg, JA | 1 |
| Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C | 1 |
| Carleo, MA; Chirianni, A; Coppola, N; De Luca, A; Esposito, V; Guerra, G; Lucariello, A; Perna, A; Sangiovanni, V; Viglietti, R | 1 |
| Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Motta, R; Verucchi, G; Viale, P | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
| Abgrall, S; Arribas, JR; Barger, D; Barrufet, P; Braun, D; Caniglia, EC; Cardoso, SW; Chrysos, G; Costagliola, D; Gill, J; Gogos, C; Hauser, C; Hernán, MA; Hoyos, SP; Justice, A; Leyes, M; Lodi, S; Logan, R; Meyer, L; Moreno, S; Muga, R; Pacheco, A; Phillips, A; Porter, K; Reiss, P; Sabin, CA; Seng, R; Tate, J; van Sighem, A; Vandenhende, MA; Winston, A | 1 |
| Andersson, LM; Edén, A; Eriksen, J; Gisslén, M; Mellgren, Å; Nilsson, S; Thalme, A; Treutiger, CJ; Tyrberg, E | 1 |
3 review(s) available for darunavir and efavirenz
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome | 2015 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
7 trial(s) available for darunavir and efavirenz
| Article | Year |
|---|---|
Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2010 |
Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Therapy, Combination; Female; Gene Expression Regulation; HIV Seronegativity; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Transport; Confidence Intervals; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Incidental Findings; Male; Membrane Transport Proteins; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2012 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Ritonavir; Sulfonamides; Young Adult | 2014 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
22 other study(ies) available for darunavir and efavirenz
| Article | Year |
|---|---|
Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Daphne; Diterpenes; Heterocyclic Compounds, 4 or More Rings; Mediterranean Region; Molecular Structure; Receptors, CXCR4 | 2012 |
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
Topics: Amides; Anti-HIV Agents; Cinnamates; Dose-Response Relationship, Drug; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Phenylpropionates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Seronegativity; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Volunteers | 2007 |
The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.
Topics: Alkynes; Benzoxazines; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; Darunavir; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reference Standards; Reproducibility of Results; Solutions; Sulfonamides | 2007 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Topics: Alkynes; Anti-Retroviral Agents; Antidepressive Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Humans; Models, Biological; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cell Extracts; Chromatography, Liquid; Cyclopropanes; Darunavir; Humans; Leukocytes, Mononuclear; Lopinavir; Mass Spectrometry; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2014 |
Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line, Tumor; Cells, Cultured; Cyclopropanes; Darunavir; Drug Resistance, Viral; Hepatocytes; Humans; Mitochondria; Neurons; Nitriles; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Rats; Reverse Transcriptase Inhibitors; Rilpivirine; Sulfonamides | 2014 |
Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Development; Calcium; Cell Differentiation; Cell Line, Tumor; Collagen Type I; Cyclopropanes; Darunavir; Dideoxynucleosides; Gene Expression Regulation, Developmental; HIV-1; Humans; Nitriles; Osteosarcoma; p21-Activated Kinases; Pyridazines; Pyrimidines; RNA, Messenger; Tenofovir; Wnt3A Protein | 2015 |
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2015 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Alkynes; Americas; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Darunavir; Europe; Female; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Meningitis, Cryptococcal; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Toxoplasmosis | 2018 |
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Darunavir; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Plasma; Sweden | 2021 |